Results for tag: "Osteoarthritis Injectables"

In the medical industry, the osteoarthritis (OA) injectables market is an important segment within the broader category of infusions and injectables, which includes a wide range of medications administered through injections to treat various conditions. OA injectables are specifically designed to target osteoarthritis, a degenerative joint disease characterized by the breakdown of cartilage and underlying bone. The treatments in this market aim to alleviate symptoms such as pain, swelling, and improve joint function. These injectables are often hyaluronic acid-based viscosupplements or corticosteroids, intended for intra-articular administration. The OA injectables market is influenced by factors such as the prevalence of OA among the aging population, advancements in injection technology, and the development of new therapeutic agents that promise longer-lasting relief and potentially disease-modifying actions. Several companies are prominently involved in the osteoarthritis injectables market. Some of the key players include Sanofi, which offers Synvisc and Synvisc-One (hylan G-F 20), and the Anika Therapeutics, which markets products such as Monovisc and Orthovisc. Pfizer is known for its product Celebrex, while Johnson & Johnson markets the drug Euflexxa. Zimmer Biomet, a company that has a portfolio of joint preservation and restoration products, offers the injectable Gel-One. These companies, among others, are continually engaged in research and development to improve and expand their offerings in the OA injectables space Show Less Read more